A
Attilio Orazi
Researcher at Texas Tech University Health Sciences Center
Publications - 337
Citations - 23869
Attilio Orazi is an academic researcher from Texas Tech University Health Sciences Center. The author has contributed to research in topics: Bone marrow & Myeloid. The author has an hindex of 62, co-authored 303 publications receiving 19600 citations. Previous affiliations of Attilio Orazi include Cornell University & Amgen.
Papers
More filters
Journal ArticleDOI
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber,Attilio Orazi,Robert P. Hasserjian,Jürgen Thiele,Michael J. Borowitz,Michelle M. Le Beau,Clara D. Bloomfield,Mario Cazzola,James W. Vardiman +8 more
TL;DR: The 2016 edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues represents a revision of the prior classification rather than an entirely new classification and attempts to incorporate new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last edition.
Journal ArticleDOI
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Ayalew Tefferi,Juergen Thiele,Attilio Orazi,Hans Michael Kvasnicka,Tiziano Barbui,Curtis A. Hanson,Giovanni Barosi,Srdan Verstovsek,Gunnar Birgegård,Ruben A. Mesa,John T. Reilly,Heinz Gisslinger,Alessandro M. Vannucchi,Francisco Cervantes,Guido Finazzi,Ronald Hoffman,D. Gary Gilliland,Clara D. Bloomfield,James W. Vardiman +18 more
TL;DR: In this paper, the authors proposed a revision of the current World Health Organization (WHO) diagnostic criteria for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which was subsequently presented by an international expert panel of pathologists and clinical investigators in myeloproliferative disorders.
Journal ArticleDOI
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation
Bihui H. Ye,Giorgio Cattoretti,Qiong Shen,Jiandong Zhang,Nicola Hawe,Rick De Waard,Cynthia C. Leung,Mahyar Nouri-Shirazi,Attilio Orazi,R. S. K. Chaganti,Paul B. Rothman,Alan M. Stall,Pier Paolo Pandolfi,Riccardo Dalla-Favera +13 more
TL;DR: BCL-6 functions as a transcriptional switch that controls germinal centre formation and may also modulate specific T-cell-mediated responses and develop an inflammatory response in multiple organs typical of a Th2-mediated hyperimmune response.
Journal ArticleDOI
European consensus on grading bone marrow fibrosis and assessment of cellularity.
Jürgen Thiele,Hans Michael Kvasnicka,Fabio Facchetti,Vito Franco,Jon van der Walt,Attilio Orazi +5 more
TL;DR: A panel of experienced European pathologists and a foreign expert evaluated a large number of representative slides of trephine biopsies from patients with myelofibrosis in an attempt to reach a consensus on how to grade cellularity and fibrosis to allow for precise grading during the disease process and after therapy.
Journal ArticleDOI
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Green,Ken H. Young,Carlo Visco,Zijun Y. Xu-Monette,Attilio Orazi,Ronald S. Go,Ole John Nielsen,Ole V. Gadeberg,Torben Mourits-Andersen,Mikael Frederiksen,Lars Moller Pedersen,Michael Boe Møller +11 more
TL;DR: The immunohistochemical DHS defined a large subset of DLBCLs with double-hit biology and was strongly associated with poor outcome in patients treated with R-CHOP.